BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37853469)

  • 1. BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8
    Li W; Zhao C; Li W; Gong Y; Ma K; Lu Y; Liu X; Zhang L; Guo F
    J Transl Med; 2023 Oct; 21(1):737. PubMed ID: 37853469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
    Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
    J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
    Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
    Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF
    Zhi J; Jia XJ; Yan J; Wang HC; Feng B; Xing HY; Jia YT
    World J Gastrointest Oncol; 2021 Dec; 13(12):2129-2148. PubMed ID: 35070047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the treatment-naive immune microenvironment in melanoma with
    Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF
    Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
    J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.
    Wang S; Kuai Y; Lin S; Li L; Gu Q; Zhang X; Li X; He Y; Chen S; Xia X; Ruan Z; Lin C; Ding Y; Zhang Q; Qi C; Li J; He X; Pathak JL; Zhou W; Liu S; Wang L; Zheng L
    BMC Med; 2023 Mar; 21(1):115. PubMed ID: 36978108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol induction in CD8
    Shuwen H; Yinhang W; Jing Z; Qiang Y; Yizhen J; Quan Q; Yin J; Jiang L; Xi Y
    Cancer Immunol Immunother; 2023 Dec; 72(12):4441-4456. PubMed ID: 37919522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.
    Lee KS; Kwak Y; Ahn S; Shin E; Oh HK; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
    Cancer Immunol Immunother; 2017 Jul; 66(7):927-939. PubMed ID: 28405764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8
    Shu S; Matsuzaki J; Want MY; Conway A; Benjamin-Davalos S; Allen CL; Koroleva M; Battaglia S; Odunsi A; Minderman H; Ernstoff MS
    Immunol Invest; 2020 Oct; 49(7):744-757. PubMed ID: 32799717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8
    Ge J; Liu SL; Zheng JX; Shi Y; Shao Y; Duan YJ; Huang R; Yang LJ; Yang T
    Transl Oncol; 2023 Aug; 34():101683. PubMed ID: 37224767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
    Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
    J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
    Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
    J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
    Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
    Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
    Martin AM; Bell WR; Yuan M; Harris L; Poore B; Arnold A; Engle EL; Asnaghi L; Lim M; Raabe EH; Eberhart CG
    J Neuropathol Exp Neurol; 2020 Jan; 79(1):74-85. PubMed ID: 31819973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.